Actinogen Medical’s pivotal XanaMIA Alzheimer’s trial has passed a third independent safety review, endorsing continuation without changes. Final topline efficacy data is expected in November 2026.
- Third positive Data Monitoring Committee safety recommendation
- 247 patients enrolled with over 100 treated for 36 weeks
- Xanamem 10 mg daily shows promising safety profile
- Trial assesses slowing of Alzheimer’s progression via CDR-SB endpoint
- Final results due November 2026
Independent Committee Confirms Safety of Xanamem in XanaMIA Trial
Actinogen Medical (ASX:ACW) has secured a third consecutive positive recommendation from the independent Data Monitoring Committee (DMC) overseeing its pivotal XanaMIA phase 2b/3 trial for Alzheimer’s disease. The DMC, composed of clinical and statistical experts unaffiliated with daily trial operations, reviewed safety data from all 247 enrolled participants, including over 100 who completed the full 36-week treatment period. Their conclusion: the trial should continue without amendment.
Safety Profile Supports Longer-Term Treatment Potential
The oral investigational drug Xanamem, dosed at 10 mg daily, continues to demonstrate a promising safety profile in patients with mild to moderate Alzheimer’s disease. This latest review did not include unblinded efficacy data, focusing solely on participant safety. Actinogen’s CEO Dr Steven Gourlay highlighted the significance, stating the results bolster confidence in Xanamem’s suitability for longer-term use and its potential to significantly slow disease progression compared to existing therapies.
Trial Design and Upcoming Milestones
The XanaMIA trial is a double-blind, placebo-controlled study conducted across Australia and the United States. It targets patients with biomarker-confirmed progressive Alzheimer’s, using elevated pTau181 protein levels as inclusion criteria. The primary endpoint is the Clinical Dementia Rating scale – Sum of Boxes (CDR-SB), a widely accepted measure of cognitive and functional decline. Recruitment has closed, and the trial’s open-label extension phase, which offers active treatment to all participants for up to 25 months, commenced in March 2026.
Final topline results from the randomized phase are expected in November 2026, a key catalyst for the company and its investors. This milestone follows a series of regulatory and funding advances, including a recent $16.8 million capital raise designed to support trial completion and further development activities.
Xanamem’s Mechanism and Broader Therapeutic Potential
Xanamem (emestedastat) operates by inhibiting the enzyme 11β-HSD1, reducing elevated cortisol levels in the brain without disrupting systemic cortisol production. Elevated brain cortisol is implicated in neuronal damage and cognitive decline in Alzheimer’s and other neuropsychiatric disorders. The drug has been studied in over 500 subjects across eight clinical trials, showing consistent target engagement and safety.
Previous trials, including the XanaCIDD phase 2a study in treatment-resistant depression, demonstrated significant improvements in depressive symptoms, reinforcing the therapeutic rationale for cortisol modulation. Actinogen is exploring Xanamem’s utility beyond Alzheimer’s, targeting a broad spectrum of neurological conditions linked to cortisol dysregulation.
Bottom Line?
With safety reviews cleared and final efficacy data due this November, Actinogen’s XanaMIA trial is entering a critical phase that could reshape treatment options for Alzheimer’s disease.
Questions in the middle?
- Will the November topline results confirm Xanamem’s efficacy in slowing Alzheimer’s progression?
- How will regulatory agencies respond to the final data given recent EMA guidance?
- What are the prospects for Xanamem’s application in other cortisol-related neurological disorders?